Catalent Pharma Solutions has completed its acquisition of R.P. Scherer Eberbach, gaining the remaining 49% interest from Gelita AG. Under full Catalent ownership, customers will have access to a wider range of drug development and delivery technologies/services, and a global supply chain network.   Catalent and Gelita have had a joint partnership for 60 years. R.P. Scherer Corp. (including the Eberbach joint venture) was founded by the inventor of the rotary die production process for softgel c...